Evonik Takeover Saga Shifts to RAG-Stiftung as Legal Opinion and Industrial Logic Raise the Stakes
Published on 11/19/2026 at 14:40 | Editorial boerse-global.deA legal opinion has turned up the heat on the RAG-Stiftung's board of trustees, pressing the body to form its own judgment on a potential BASF takeover of Evonik rather than simply deferring to the specialty chemicals maker's management. The foundation controls roughly 43% of Evonik, which makes its stance — alongside the company's own resistance — a decisive factor in whether any deal can advance.
Scrutiny, however, is a long way from a sale. Evonik has rejected the approach on multiple occasions, and Handelsblatt reports that no talks are currently underway between the two companies. Neither BASF nor Evonik has commented on speculation that a sweeter bid might be in the works.
A Mandate to Assess, Not to Sell
The opinion calls on the trustees to reach their own valuation of the offer — a question distinct from management's repeated refusal. Nothing in the demand to review the bid implies the foundation wants to sell, nor that Evonik would open negotiations. Among those sitting on the board is Hendrik Wüst, premier of North Rhine-Westphalia, who came out against a sale yesterday, citing the need to preserve the state's industrial core. Around 11,000 people work for Evonik in NRW. Wüst's public opposition is not, however, a formal resolution of the trustees.
In a parallel development, Evonik's labor director Thomas Wessel is reportedly weighing a move to the RAG-Stiftung's executive board, according to manager magazin. The possible personnel change lands squarely in the middle of the takeover debate, though no decision on the appointment has been tied to it.
Should investors sell immediately? Or is it worth buying Evonik?
Price Talk Remains Unconfirmed
Citing insiders, Handelsblatt reports that a bid of EUR 26 to EUR 28 per Evonik share could break the deadlock. The figure on the table so far has been EUR 24 per share. The higher range is not a confirmed offer.
Shareholders therefore face two separate questions: whether BASF actually raises its bid, and how the RAG-Stiftung values the proposal. The legal opinion addresses the second — ratcheting up pressure on the trustees to reach an independent view without prejudging the outcome.
Money Alone Won't Clear the Hurdles
Even a richer price may not be enough to get BASF over the line. According to a Reuters report yesterday, sources close to Evonik say the Ludwigshafen group would also need to present a convincing industrial rationale for the combination. For investors, the size of any revised offer is only part of the story; equally important is whether BASF can overcome resistance to the transaction.
Two sources close to Evonik told Reuters that a financial sweetener would not automatically secure backing for a deal. Evonik regards itself as well positioned on a standalone basis and has turned down earlier approaches. BASF and Evonik both declined to comment on the reports.
That leaves two distinct obstacles in place: valuation and strategic merit. Even if BASF moves closer to the other side's price expectations, the question of industrial logic would remain unanswered. Evonik's attachment to independence, in other words, cannot be reduced to a demand for more money.
Analysts are keeping their distance. LBBW reportedly lifted its Evonik price target to EUR 23 from EUR 22 while reaffirming its "Hold" rating — a cautious stance despite the chatter about a higher bid.
Assurances Fall Short of a Deal
BASF has dangled possible commitments on sites, jobs and apprenticeships before the NRW state government and the RAG-Stiftung. According to the Börsen-Zeitung, the company also pitched proposals on investment and research. Those concrete pledges, however, remained placeholders.
For Evonik, the question is how binding those safeguards would be. The outlined proposals are not a negotiated agreement, and they do not by themselves answer the demand from Evonik's camp for a persuasive industrial case.
Evonik at a turning point? This analysis reveals what investors need to know now.
The RAG-Stiftung holds the key to any sale: its board of trustees would have to approve a disposal of its Evonik stake. The body includes WĂĽst, who views the takeover plans with deep skepticism, and economics minister Mona Neubaur, who also opposes the combination.
A Calendar Date, Not a Decision
Per Börsen-Zeitung, the RAG-Stiftung's trustees meet next Wednesday. No new offer was on the agenda as of that report, making the meeting an important waypoint in the process rather than an announced verdict on a sale.
The market's reaction underscores the uncertainty. Despite speculation about an improved bid, Evonik closed yesterday's session down 1.5% — the prospect of a higher price was not enough to deliver a positive finish.
For investors, the crucial distinction remains that between a discussed price range and a workable transaction. Only a confirmed new offer would put flesh on the financial terms. Whether a takeover follows will depend, beyond that, on the industrial rationale, credible commitments and the necessary approval from the RAG-Stiftung.
Ad
Evonik Stock: New Analysis - 19 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
